<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">EE069</CoID>
		<CoID Type="CompanyName">Circassia Pharmaceuticals PLC</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">CIR</IssueID>
			<IssueID Type="CUSIP">G21477107</IssueID>
			<IssueID Type="ISIN">GB00BJVD3B28</IssueID>
			<IssueID Type="RIC">CIRCI.L</IssueID>
			<IssueID Type="SEDOL">BJVD3B2</IssueID>
			<IssueID Type="DisplayRIC">CIRCI.L</IssueID>
			<IssueID Type="InstrumentPI">152493269</IssueID>
			<IssueID Type="QuotePI">152508390</IssueID>
			<Exchange Code="LON" Country="GBR">London Stock Exchange (LON)</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2015-07-30</LastModified>
		<LatestAvailableAnnual>2014-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2014-12-31">63</Employees>
		<SharesOut Date="2015-08-28" TotalFloat="247983991.0">284889171.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">0.70681</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-06-24T04:00:29">Circassia Pharmaceuticals plc (Circassia) is a United Kingdom-based specialty biopharmaceutical company focused on the development of immunotherapies. The Company designs immunotherapies to treat a range of common allergies and autoimmune conditions. The Company's treatment, Cat-SPIRE is in the final Phase of testing for cat allergy. Circassia's pipeline of immunotherapies is based on its ToleroMune technology. ToleroMune identifies T cell epitopes, which are short linear stretches of amino acids in allergen sequence; binds to antigen presenting cells to induce regulatory T cells and identified from blood of allergic individuals. The Company also has completed the Phase IIb study for Ragweed-SPIRE, Grass-SPIRE and House Dust Mite (HDM)-SPIRE.</Text>
		<Text Type="Financial Summary" lastModified="2015-07-30T07:07:13">BRIEF: For the six months ended 30 June 2015, Circassia Pharmaceuticals PLC revenues increased from L0K to L574K. Net loss increased 33% to L21.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Administrative expenses increase from L3.1M to L7.2M (expense), Research and development costs increase of 12% to L18.4M (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2015-12-10T07:26:26">
		<streetAddress line="1">The Magdalen Centre</streetAddress>
		<streetAddress line="2">Robert Robinson Avenue</streetAddress>
		<streetAddress line="3">The Oxford Science Park</streetAddress>
		<city>OXFORD</city>
		<state-region></state-region>
		<postalCode>OX4 4GA</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1865</city-areacode>
				<number>405560</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1865</city-areacode>
				<number>784576</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2015-10-09T00:01:03"><webSite mainCategory="Home Page">http://www.circassia.com/</webSite><eMail mainCategory="Company Contact/E-mail">info@circassia.co.uk</eMail></webLinks>
	<peerInfo lastUpdated="2015-12-10T07:26:26">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201011" mnem="">Bio Therapeutic Drugs</Industry>
			<Industry type="NAICS" order="1" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="09/01/2013">
			<firstName>Francesco</firstName>
			<mI></mI>
			<lastName>Granata</lastName>
			<age>64 </age>
			<title startYear="2013" startMonth="09" startDay="01" iD1="CHM" abbr1="Chmn." iD2="NED" abbr2="Non Ex. Dir.">Non-Executive Chairman of the Board</title>
		</officer>
		<officer rank="2" since="NA">
			<firstName>Steven</firstName>
			<mI></mI>
			<lastName>Harris</lastName>
			<age>48 </age>
			<title startYear="NA" startMonth="" startDay="" iD1="CEO" abbr1="CEO" iD2="EDR" abbr2="Exec. Dir.">Chief Executive Officer, Executive Director</title>
		</officer>
		<officer rank="3" since="01/05/2012">
			<firstName>Julien</firstName>
			<mI></mI>
			<lastName>Cotta</lastName>
			<age>51 </age>
			<title startYear="2013" startMonth="11" startDay="26" iD1="CFO" abbr1="CFO" iD2="EDR" abbr2="Exec. Dir.">Chief Financial Officer, Executive Director</title>
		</officer>
		<officer rank="4" since="NA">
			<firstName>Rod</firstName>
			<mI></mI>
			<lastName>Hafner</lastName>
			<age>49 </age>
			<title startYear="2008" startMonth="03" startDay="10" iD1="SVP" abbr1="Sr. VP" iD2="EDR" abbr2="Exec. Dir.">Senior Vice President - Research &amp; Development, Executive Director</title>
		</officer>
		<officer rank="5" since="01/2014">
			<firstName>Steve</firstName>
			<mI></mI>
			<lastName>Pawsey</lastName>
			<age></age>
			<title startYear="2014" startMonth="01" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Chief Medical Officer</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2014-12-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">2.74500</Ratio>
			<Ratio FieldName="NHIG" Type="N">3.56000</Ratio>
			<Ratio FieldName="NLOW" Type="N">2.41100</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">0.22186</Ratio>
			<Ratio FieldName="EV" Type="N">595.43080</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">782.02080</Ratio>
			<Ratio FieldName="AREV" Type="N">0.00000</Ratio>
			<Ratio FieldName="AEBITD" Type="N">-45.78900</Ratio>
			<Ratio FieldName="ANIAC" Type="N">-35.10800</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">-0.20759</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.00000</Ratio>
			<Ratio FieldName="ABVPS" Type="N">1.00707</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.98506</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">-0.20745</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">-31.80764</Ratio>
			<Ratio FieldName="APR2REV" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">2.72573</Ratio>
			<Ratio FieldName="Employees" Type="N">63</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2015" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2015" CurInterimEndMonth="9" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">1.25</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">4.39000</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-11.51764</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">9.90000</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-0.23833</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-71.67500</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
